수막구균 백신 시장 분석 및 예측(-2035년) : 유형, 제품, 기술, 용도, 최종 사용자, 투여 방법, 개발 단계

The global Meningococcal Vaccines Market is projected to grow from $4.1 billion in 2025 to $8.9 billion by 2035, at a compound annual growth rate (CAGR) of 7.9%. The global meningococcal vaccines market continues expanding as governments strengthen routine immunization programs and outbreak preparedness strategies. According to the World Health Organization (WHO), meningococcal disease remains a significant public health concern despite declining incidence in vaccinated populations, encouraging sustained vaccine procurement. The WHO-led rollout of meningococcal A conjugate vaccines across Africa has vaccinated hundreds of millions of individuals, substantially reducing epidemic occurrence. Industry assessments indicate the global market is valued at over USD 4 billion in 2025, with projected compound annual growth exceeding 7% through the forecast period, supported by expanding MenB adoption and next-generation multivalent vaccine development.

Polysaccharide vaccines have historically served outbreak control and short-term immunization but offer limited immunological memory, restricting long-term protection. Conjugate vaccines dominate clinical practice due to superior immune response, herd immunity benefits, and prolonged protection across different age groups, making them central to national immunization schedules. Combination vaccines integrate protection against multiple meningococcal serogroups, improving vaccination efficiency while reducing healthcare visits and administration costs. Continued advancements in conjugation technologies, broader serogroup coverage, and increasing government-supported immunization programs are expected to sustain innovation and market expansion across developed and emerging healthcare systems.

MenACWY vaccines represent the largest product category owing to broad protection against four clinically significant serogroups and widespread inclusion in adolescent immunization schedules. MenB vaccines are witnessing increasing adoption following recommendations in countries addressing serogroup B outbreaks. MenC and MenA vaccines continue serving region-specific immunization requirements, particularly where disease prevalence remains concentrated. MenAC formulations support targeted vaccination initiatives, while MenACWY-CRM and MenACWY-TT conjugate products provide enhanced immunogenicity through different carrier proteins. Product innovation increasingly focuses on expanded serogroup protection, improved durability, and simplified vaccination schedules supporting long-term commercial growth.

Geographical Overview

North America maintains a substantial share of the meningococcal vaccines market through comprehensive immunization infrastructure, favorable reimbursement systems, and strong public health surveillance. The region benefits from routine adolescent vaccination recommendations, extensive healthcare access, and established procurement frameworks supporting consistent vaccine demand. Leading pharmaceutical manufacturers maintain significant research, manufacturing, and commercialization capabilities across the region, accelerating product innovation and regulatory approvals. Continuous investments in advanced conjugate and multivalent vaccines, combined with institutional vaccination requirements for schools, colleges, and military personnel, reinforce stable market expansion and sustained commercial opportunities.

Asia-Pacific demonstrates significant market development supported by expanding immunization coverage, rising healthcare expenditure, and increasing awareness of vaccine-preventable diseases. Governments continue strengthening national vaccination programs while improving cold-chain infrastructure and healthcare accessibility. Population growth, urbanization, and enhanced disease surveillance encourage broader vaccine adoption across pediatric and adolescent populations. International partnerships, domestic vaccine manufacturing investments, and regulatory modernization are improving supply capabilities throughout the region. Growing participation from regional biotechnology companies and increasing procurement by public health agencies position Asia-Pacific for sustained demand and long-term industry development.

Key Trends and Drivers

Technological Advancements in Vaccine Development:

The meningococcal vaccines market is experiencing significant growth due to technological advancements in vaccine development. Innovations such as conjugate vaccines and recombinant DNA technology have enhanced the efficacy and safety profiles of meningococcal vaccines. These technologies enable the production of vaccines that provide broader protection against multiple serogroups of Neisseria meningitidis, the bacteria responsible for meningococcal disease. As a result, there is a growing adoption of these advanced vaccines in immunization programs worldwide, contributing to market expansion.

Government Vaccination Policies Accelerate Market Growth:

Growing government commitment toward routine immunization and outbreak prevention remains the primary driver of market expansion. Rising awareness of invasive meningococcal disease, strengthened surveillance systems, and recommendations from global health organizations encourage broader vaccine coverage among infants, adolescents, travelers, and high-risk populations. Public procurement initiatives, school-entry vaccination policies, and expanding healthcare infrastructure continue stimulating demand while supporting long-term investments in vaccine research, production, and distribution.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Mode
• 2.7 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Conjugate Vaccines
  • 4.1.2 Polysaccharide Vaccines
  • 4.1.3 Subcapsular Vaccines
  • 4.1.4 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 MenACWY
  • 4.2.2 MenB
  • 4.2.3 MenC
  • 4.2.4 MenA
  • 4.2.5 MenAC
  • 4.2.6 MenABCWY
  • 4.2.7 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Recombinant DNA Technology
  • 4.3.2 Cell Culture Technology
  • 4.3.3 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Pediatrics
  • 4.4.2 Adults
  • 4.4.3 Travelers
  • 4.4.4 Military Personnel
  • 4.4.5 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Academic and Research Institutes
  • 4.5.4 Others
• 4.6 Market Size & Forecast by Mode (2020-2035)
  • 4.6.1 Injection
  • 4.6.2 Nasal Spray
  • 4.6.3 Others
• 4.7 Market Size & Forecast by Stage (2020-2035)
  • 4.7.1 Preclinical
  • 4.7.2 Clinical Trials
  • 4.7.3 Commercialized
  • 4.7.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Mode
    • 5.2.1.7 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Mode
    • 5.2.2.7 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Mode
    • 5.2.3.7 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Mode
    • 5.3.1.7 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Mode
    • 5.3.2.7 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Mode
    • 5.3.3.7 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Mode
    • 5.4.1.7 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Mode
    • 5.4.2.7 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Mode
    • 5.4.3.7 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Mode
    • 5.4.4.7 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Mode
    • 5.4.5.7 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Mode
    • 5.4.6.7 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Mode
    • 5.4.7.7 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Mode
    • 5.5.1.7 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Mode
    • 5.5.2.7 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Mode
    • 5.5.3.7 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Mode
    • 5.5.4.7 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Mode
    • 5.5.5.7 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Mode
    • 5.5.6.7 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Mode
    • 5.6.1.7 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Mode
    • 5.6.2.7 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Mode
    • 5.6.3.7 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Mode
    • 5.6.4.7 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Mode
    • 5.6.5.7 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Pfizer
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 GlaxoSmithKline
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Sanofi
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Merck
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Novartis
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Bharat Biotech
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Serum Institute of India
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Biomed
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Janssen Pharmaceuticals
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Emergent BioSolutions
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 CSL Limited
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Biological E
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Hualan Biological Engineering
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Walvax Biotechnology
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Chongqing Zhifei Biological Products
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Panacea Biotec
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Mitsubishi Tanabe Pharma
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Dynavax Technologies
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Valneva
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Incepta Vaccine
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us